SCHEMBL1615754

SCHEMBL1615754

CCOC(=O)c1cc(N)c2c(Cl)cc(Cl)cc2n1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.46
NQO2 P16083 4/20 0.45
CYP1A2 P05177 1/20 0.44
GABRA2 P47869 4/20 0.44
GABRB2 P47870 4/20 0.44
MEN1 O00255 1/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
AURKA O14965 1/20 0.41
AURKB Q96GD4 1/20 0.41
ADORA2A P29274 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29617388 1.00 ALDH1A1 (0.46) ALDH1A1POLBMAPK1NQO2CYP1A2
SCHEMBL9462723 0.85 NQO2 (0.52) ALDH1A1NQO2CYP1A2GABRA2GABRB2
SCHEMBL8946324 0.85 NQO2 (0.61) ALDH1A1NQO2NPC1MAPTRAB9A
SCHEMBL8946246 0.82 CYP1A2 (0.42) ALDH1A1MAPK1NQO2CYP1A2GABRA2
SCHEMBL19152266 0.82 GABRA2 (0.42) ALDH1A1POLBMAPK1NQO2CYP1A2
SCHEMBL9391555 0.79 NQO2 (0.40) NQO2CYP1A2MEN1KMT2A
SCHEMBL9463492 0.78 NQO2 (0.47) ALDH1A1NQO2CYP1A2GABRA2GABRB2
SCHEMBL3327719 0.76 CYP1A2 (0.61) ALDH1A1POLBMAPK1CYP1A2GABRA2
SCHEMBL1617936 0.76 GABRA2 (0.42) ALDH1A1MAPK1NQO2CYP1A2GABRA2
SCHEMBL17372703 0.74 GLP1R (0.48) ALDH1A1MAPK1CYP1A2GABRA2GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4227297-A1 PROCESS FOR PREPARING DIPHENYLUREIDO-DIHALOKYNURENIC ACIDS AND TOSYLATE ADDITION SALTS THEREOF Lohocla Research Corporation (US) 2023-08-16 EP disclosed
EP-4227297-A1 PROCESS FOR PREPARING DIPHENYLUREIDO-DIHALOKYNURENIC ACIDS AND TOSYLATE ADDITION SALTS THEREOF Lohocla Research Corporation (US) 2023-08-16 EP disclosed
US-20220162168-A1 PROCESS FOR PREPARING DIPHENYLUREIDO-DIHALOKYNURENIC ACIDS AND TOSYLATE ADDITION SALTS THEREOF LOHOCLA RESEARCH CORPORATION 2022-05-26 US disclosed
US-20220162168-A1 PROCESS FOR PREPARING DIPHENYLUREIDO-DIHALOKYNURENIC ACIDS AND TOSYLATE ADDITION SALTS THEREOF LOHOCLA RESEARCH CORPORATION 2022-05-26 US disclosed
US-11130737-B2 Multifunctional aminoquinoline therapeutic agents LOHOCLA RESEARCH CORPORATION (US) 2021-09-28 US disclosed
EP-3846813-A1 ANALGESIC COMPOSITIONS Lohocla Research Corporation (US) 2021-07-14 EP disclosed
US-10875831-B1 Process for preparing 1,4-dihydro-4-oxoquinoline-2-carboxylates and 4-aminoquinoline compounds therefrom LOHOCLA RESEARCH CORPORATION (US) 2020-12-29 US disclosed
US-10875831-B1 Process for preparing 1,4-dihydro-4-oxoquinoline-2-carboxylates and 4-aminoquinoline compounds therefrom LOHOCLA RESEARCH CORPORATION (US) 2020-12-29 US disclosed
US-20200095204-A1 MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS LOHOCLA RESEARCH CORPORATION 2020-03-26 US disclosed
US-10435371-B2 Multifunctional aminoquinoline therapeutic agent LOHOCLA RESEARCH CORPORATION (US) 2019-10-08 US disclosed
US-20110184018-A1 METHOD FOR TREATING PERIPHERAL NEUROPATHIC PAIN LOHOCLA RESEARCH CORPORATION (US) 2011-07-28 US disclosed
US-7923458-B2 Method for treating chronic pain LOHOCLA RESEARCH CORPORATION (US) 2011-04-12 US disclosed
US-7923458-B2 Method for treating chronic pain LOHOCLA RESEARCH CORPORATION (US) 2011-04-12 US disclosed
US-7923458-B2 Method for treating chronic pain LOHOCLA RESEARCH CORPORATION (US) 2011-04-12 US disclosed
US-20090137627-A1 Method for Treating Chronic Pain LOHOCLA RESEARCH CORPORATION 2009-05-28 US disclosed
US-20090137627-A1 Method for Treating Chronic Pain LOHOCLA RESEARCH CORPORATION 2009-05-28 US disclosed
US-20090137627-A1 Method for Treating Chronic Pain LOHOCLA RESEARCH CORPORATION 2009-05-28 US disclosed
EP-1951238-A2 METHOD FOR TREATING CHRONIC PAIN Lohocla Research Corporation (US) 2008-08-06 EP disclosed
WO-2007044682-A2 METHOD FOR TREATING CHRONIC PAIN LOHOCLA RESEARCH CORPORATION (US) 2007-04-19 WO disclosed
WO-2007044682-A2 METHOD FOR TREATING CHRONIC PAIN LOHOCLA RESEARCH CORPORATION (US) 2007-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11130737-B2 Multifunctional aminoquinoline therapeutic agents OPRK1, OPRM1, OPRD1 ALDH1A1 233/4885POLB 2632/4885MAPK1 2310/4885
US-20090137627-A1 Method for Treating Chronic Pain OPRK1, AADAT, BDKRB2 ALDH1A1 930/4885POLB 4165/4885MAPK1 3630/4885
US-20110184018-A1 METHOD FOR TREATING PERIPHERAL NEUROPATHIC PAIN CNR1, CNR2, OPRK1 ALDH1A1 2774/4885POLB 3577/4885MAPK1 1719/4885
US-20200095204-A1 MULTIFUNCTIONAL AMINOQUINOLINE THERAPEUTIC AGENTS OPRK1, OPRM1, OPRD1 ALDH1A1 233/4885POLB 2632/4885MAPK1 2310/4885
US-10875831-B1 Process for preparing 1,4-dihydro-4-oxoquinoline-2-carboxylates and 4-aminoquinoline compounds therefrom KMO, THEM6, HADHA ALDH1A1 1660/4885POLB 3846/4885MAPK1 2774/4885
US-10435371-B2 Multifunctional aminoquinoline therapeutic agent OPRK1, OPRM1, OPRD1 ALDH1A1 220/4885POLB 2753/4885MAPK1 2551/4885
US-20220162168-A1 PROCESS FOR PREPARING DIPHENYLUREIDO-DIHALOKYNURENIC ACIDS AND TOSYLATE ADDITION SALTS THEREOF KMO, KYNU, PAH ALDH1A1 979/4885POLB 3643/4885MAPK1 1167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.